ACORDA THERAPEUTICS, INC. Financials Acorda Therapeutics, Inc. Nasdaq
Equities
ACOR
US00484M7002
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.73 USD | -2.67% |
|
+92.11% | -95.16% |
| Apr. 15 | Acorda Therapeutics Delisted from Nasdaq, Now Trading on OTC Pink Market | MT |
| 2023 | Transcript : Acorda Therapeutics, Inc., Q2 2023 Earnings Call, Aug 08, 2023 |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | - | - | - | - | - | - |
| Enterprise Value (EV) 1 | - | - | - | - | - | - |
| P/E ratio | 21.9 x | -0.35 x | -0.34 x | -0.24 x | -0.23 x | -0.07 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - |
| Price to Book | 1.21 x | 0.31 x | 0.16 x | 0.21 x | 0.2 x | -0.12 x |
| Nbr of stocks (in thousands) | - | - | - | - | - | - |
| Reference price 2 | 1,870 | 244.8 | 82.81 | 47.80 | 15.33 | 15.09 |
| Announcement Date | 2/27/19 | 2/28/20 | 3/16/21 | 3/18/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 471.4 | 192.4 | 153 | 129.1 | 118.6 | 117.6 |
| EBITDA 1 | 106.3 | -82.63 | -45.66 | -37.65 | -9.076 | 8.402 |
| EBIT 1 | 94.79 | -116.6 | -86.55 | -71.3 | -41.78 | -23.26 |
| Operating Margin | 20.11% | -60.6% | -56.58% | -55.24% | -35.24% | -19.78% |
| Earnings before Tax (EBT) 1 | 20.42 | -274.2 | -107.7 | -109.1 | -35.25 | -296 |
| Net income 1 | 33.68 | -273 | -99.59 | -104 | -65.92 | -252.9 |
| Net margin | 7.14% | -141.87% | -65.11% | -80.54% | -55.59% | -214.95% |
| EPS 2 | 85.20 | -690.0 | -246.4 | -195.8 | -66.90 | -203.6 |
| Free Cash Flow 1 | 106.6 | -168.6 | -101.7 | 72.58 | 13.07 | 20.14 |
| FCF margin | 22.6% | -87.63% | -66.5% | 56.23% | 11.02% | 17.13% |
| FCF Conversion (EBITDA) | 100.28% | - | - | - | - | 239.76% |
| FCF Conversion (Net income) | 316.37% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 2/27/19 | 2/28/20 | 3/16/21 | 3/18/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 148 | 204 | 150 | 135 | 161 |
| Net Cash position 1 | 71.1 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | -1.793 x | -4.465 x | -3.978 x | -14.92 x | 19.15 x |
| Free Cash Flow 1 | 107 | -169 | -102 | 72.6 | 13.1 | 20.1 |
| ROE (net income / shareholders' equity) | 5.95% | -59.2% | -36.3% | -53.4% | -53.9% | 786% |
| ROA (Net income/ Total Assets) | 4.74% | -6.94% | -7.55% | -8.19% | -6.14% | -5.77% |
| Assets 1 | 710 | 3,932 | 1,319 | 1,269 | 1,074 | 4,383 |
| Book Value Per Share 2 | 1,549 | 782.0 | 503.0 | 228.0 | 76.90 | -127.0 |
| Cash Flow per Share 2 | 743.0 | 156.0 | 151.0 | 68.90 | 30.80 | 24.10 |
| Capex 1 | 33.3 | 90.4 | 4.39 | 0.17 | 0.14 | 0.26 |
| Capex / Sales | 7.07% | 47% | 2.87% | 0.13% | 0.11% | 0.22% |
| Announcement Date | 2/27/19 | 2/28/20 | 3/16/21 | 3/18/22 | 3/15/23 | 4/1/24 |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ACOR.Q Stock
- ACOR Stock
- Financials Acorda Therapeutics, Inc.
